New Compounds Reduce Alcoholics’ Impulse To Drink

New Compounds Reduce Alcoholics’ Impulse To Drink
Alcoholism inflicts a heavy physical, emotional and financial toll on individuals and society. Now new discoveries and promising animal studies are offering a glimmer of hope that a new class of drugs could treat the disease without many of the unwanted side effects caused by current therapies. The researchers are presenting the results of their work at the 250th National Meeting & Exposition of the American Chemical Society (ACS).
The exact causes of alcoholism are not well understood, but the researchers explain that the urge to drink is related to the brain’s pleasure centers. Scientists have found that alcohol triggers the brain to release dopamine, the same neurochemical whose levels increase in response to pleasurable behavior like eating, sex or listening to music.
Some drugs currently available to treat alcoholism are aimed at dopamine. But these medications, derived from a class of compounds called opioid antagonists, cause depression in some patients. And they’re addictive themselves, which can lead to drug abuse. Valium is an example of another common drug used to treat alcoholism that is also addictive.
Looking for an alternative, the researchers focused on a group of molecules, called beta-carboline, known to cause some of the same results as Valium and the opioid antagonists without the unwanted side effects. They conducted laboratory tests to understand the effects of these new compounds and to discover which ones work best.
In tests using rats bred to crave alcohol, the scientists found that administering these compounds drastically diminished the rats’ drinking. What’s more, they observed very few of the side effects common to alcoholism treatment drugs, such as depression and losing the ability to experience pleasure. The drugs appeared to reduce anxiety in “alcoholic” rats, but not in control rats. Because this is different from what is seen with current drugs, the researchers think the result hints that the new compounds work much differently than opioid antagonists. As such, the beta-carbolines may also be less addictive.
The group is continuing to test the compounds in additional animal studies. The researchers have patented several of the most promising compounds, and he is starting to explore possible partnerships with drug makers that could lead to medications. If everything works out, a drug could be ready for the market in five to six years.
Based on material originally posted by American Chemical Society.
(Image source)